Zhenya Lindgardt Sells 20,755 Shares of Sera Prognostics (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 20,755 shares of the firm’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total transaction of $43,170.40. Following the completion of the transaction, the chief executive officer directly owned 871,999 shares of the company’s stock, valued at $1,813,757.92. This represents a 2.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sera Prognostics Stock Down 3.5%

Shares of SERA stock opened at $1.93 on Friday. Sera Prognostics, Inc. has a 52 week low of $1.50 and a 52 week high of $4.09. The stock has a market capitalization of $75.58 million, a PE ratio of -2.97 and a beta of 0.94. The firm has a 50 day moving average of $2.03 and a two-hundred day moving average of $2.54.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.07 million. Sera Prognostics had a negative return on equity of 41.02% and a negative net margin of 56,385.97%. Analysts expect that Sera Prognostics, Inc. will post -0.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Sera Prognostics

A number of institutional investors and hedge funds have recently bought and sold shares of SERA. Captrust Financial Advisors lifted its position in Sera Prognostics by 20.0% in the second quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after acquiring an additional 100,366 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new stake in Sera Prognostics in the first quarter valued at $193,000. Balentine LLC purchased a new stake in Sera Prognostics in the third quarter valued at $258,000. Jane Street Group LLC purchased a new stake in Sera Prognostics in the fourth quarter valued at $203,000. Finally, Vanguard Group Inc. lifted its position in Sera Prognostics by 4.6% in the third quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock valued at $3,725,000 after acquiring an additional 54,008 shares during the last quarter. 54.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Craig Hallum assumed coverage on shares of Sera Prognostics in a research report on Thursday, June 4th. They set a “buy” rating and a $6.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sera Prognostics in a research report on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Sera Prognostics currently has an average rating of “Moderate Buy” and an average target price of $5.50.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.